---
title: "Patient-derived organoids predict clinical response: a patient in the lab"
description: Check how patient-derived organoids can predict patient response, and enable efficient decision making early in the drug development pipeline.
image: https://resources.huborganoids.nl/hubfs/elrig22-poster-patient-derived-organoids.jpg
---

[![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")](https://huborganoids.nl/)

![merk-m-logo-blue](https://resources.huborganoids.nl/hs-fs/hubfs/merk-m-logo-blue.png?width=728&height=225&name=merk-m-logo-blue.png)

# Patient-derived organoids predict clinical response: a patient in the lab

![ELRIG 2022 Poster](https://resources.huborganoids.nl/hs-fs/hubfs/Assets%202022/elrig-2022-poster-patient-derived-organoids.png?width=300&name=elrig-2022-poster-patient-derived-organoids.png)

A large fraction of the colorectal cancer patients diagnosed with *de novo* metastatic disease (mCRC) do not benefit from current standard of care and experience substantial side effects. Therefore, there is an urgent need for advanced preclinical models to predict clinical response.

Patient-derived organoids (PDO) can be developed from healthy as well as diseased tissue, including cancer lesions, and therefore faithfully recapitulate patient disease *in vitro*, and can be propagated for drug testing in a matter of weeks.

#### Download our poster to discover:

- The establishment and characterization of a biobank of mCRC organoids
- Validation data on the predictive value of PDOs in the stratification of mCRC patients
- Current efforts on the establishment of an automated system for selecting, picking, and placing organoids for accelerating drug screening in organoids

### Download our poster

![Logo HUB Organoids](https://resources.huborganoids.nl/hubfs/raw_assets/public/HUBOrganoids_May2021/images/logo-huborganoids-white.svg "Logo HUB Organoids")

[Privacy Policy](https://huborganoids.nl/privacy-policy)

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

***FOR RESEARCH USE ONLY.**  Unless otherwise stated in our catalog or other company documentation  
 accompanying the product(s), our products are intended for research use only and are not to be used   
 for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro   
 diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to   
humans or animals.*